SMT201600129B - Trattamento della lipodistrofia - Google Patents

Trattamento della lipodistrofia

Info

Publication number
SMT201600129B
SMT201600129B SM201600129T SM201600129T SMT201600129B SM T201600129 B SMT201600129 B SM T201600129B SM 201600129 T SM201600129 T SM 201600129T SM 201600129 T SM201600129 T SM 201600129T SM T201600129 B SMT201600129 B SM T201600129B
Authority
SM
San Marino
Prior art keywords
lipodystrophy
treatment
Prior art date
Application number
SM201600129T
Other languages
English (en)
Inventor
Dhiraj Gambhire
Rajendrakumar Hariprasad Jani
Bipin Pandey
Kaushik Sata
Himanshu Kothari
Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of SMT201600129B publication Critical patent/SMT201600129B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ceramic Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
SM201600129T 2011-01-31 2016-05-04 Trattamento della lipodistrofia SMT201600129B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN257MU2011 2011-01-31
PCT/IN2012/000069 WO2012104869A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy

Publications (1)

Publication Number Publication Date
SMT201600129B true SMT201600129B (it) 2016-07-01

Family

ID=54192841

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600129T SMT201600129B (it) 2011-01-31 2016-05-04 Trattamento della lipodistrofia

Country Status (29)

Country Link
US (3) US10017470B2 (it)
EP (2) EP3009136A1 (it)
JP (2) JP2014504610A (it)
KR (3) KR20130128451A (it)
CN (2) CN103354757A (it)
AP (1) AP3920A (it)
AU (2) AU2012212992B2 (it)
BR (1) BR112013019352A2 (it)
CA (1) CA2825456C (it)
CL (1) CL2013002166A1 (it)
CO (1) CO6781497A2 (it)
CY (1) CY1117564T1 (it)
DK (1) DK2670486T3 (it)
EA (1) EA025421B1 (it)
ES (1) ES2569248T3 (it)
HR (1) HRP20160403T1 (it)
HU (1) HUE027512T2 (it)
IL (2) IL227266B (it)
ME (1) ME02392B (it)
MX (1) MX350611B (it)
MY (1) MY191100A (it)
PH (1) PH12013501533A1 (it)
PL (1) PL2670486T3 (it)
RS (1) RS54735B1 (it)
SG (1) SG191772A1 (it)
SI (1) SI2670486T1 (it)
SM (1) SMT201600129B (it)
UA (1) UA110813C2 (it)
WO (1) WO2012104869A1 (it)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2988736A1 (en) 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (it) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) * 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (it) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
EP3933845A3 (en) 2014-10-27 2022-06-22 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3270931A4 (en) * 2015-02-27 2018-10-03 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
US12201609B2 (en) 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
US12201611B2 (en) 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof
WO2025115040A1 (en) * 2023-12-01 2025-06-05 Zydus Lifesciences Limited Novel co-crystals of saroglitazar and saroglitazar mg salt
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
PT826688E (pt) 1995-04-28 2002-02-28 Daiichi Seiyaku Co Composto pentaciclico
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE69723070T2 (de) 1996-12-24 2005-02-17 Daewoo Motor Co., Ltd. Abgasrückführventil für brennkraftmaschine
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CN1266129C (zh) 2000-01-19 2006-07-26 卡地拉健康护理有限公司 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
TR201810393T4 (tr) 2009-11-26 2018-08-27 Genfit Karaciğer rahatıszlıklarının tedavisi için 1,3-difenilprop-2-en-1-on türevlerinin kullanımı.
CN103347506A (zh) 2010-10-12 2013-10-09 约翰.霍普金斯大学 包含美金刚的镇咳组合物
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
EP2988736A1 (en) 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (it) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (it) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
HRP20160403T1 (hr) 2016-06-03
CL2013002166A1 (es) 2014-04-11
RS54735B1 (sr) 2016-10-31
JP2016028069A (ja) 2016-02-25
US20130338209A1 (en) 2013-12-19
AU2012212992A1 (en) 2013-07-25
HUE027512T2 (en) 2016-10-28
KR20150100949A (ko) 2015-09-02
PH12013501533A1 (en) 2013-09-16
AP2013006988A0 (en) 2013-07-31
KR20160038073A (ko) 2016-04-06
EA201391108A1 (ru) 2013-12-30
NZ612804A (en) 2015-09-25
SI2670486T1 (sl) 2016-09-30
CN103354757A (zh) 2013-10-16
AP3920A (en) 2016-12-02
CA2825456A1 (en) 2012-08-09
ME02392B (me) 2016-09-20
PL2670486T3 (pl) 2016-08-31
CN107056671A (zh) 2017-08-18
US10017470B2 (en) 2018-07-10
IL262611A (en) 2018-12-31
US9783495B2 (en) 2017-10-10
MX350611B (es) 2017-09-11
KR101633720B1 (ko) 2016-06-27
CA2825456C (en) 2016-01-05
SG191772A1 (en) 2013-08-30
US20170088514A1 (en) 2017-03-30
JP5956664B2 (ja) 2016-07-27
WO2012104869A1 (en) 2012-08-09
IL227266A0 (en) 2013-09-30
EP3009136A1 (en) 2016-04-20
IL227266B (en) 2019-10-31
BR112013019352A2 (pt) 2020-07-14
DK2670486T3 (en) 2016-05-17
JP2014504610A (ja) 2014-02-24
AU2015249076A1 (en) 2015-11-12
ES2569248T3 (es) 2016-05-09
KR20130128451A (ko) 2013-11-26
CO6781497A2 (es) 2013-10-31
UA110813C2 (uk) 2016-02-25
EP2670486A1 (en) 2013-12-11
MY191100A (en) 2022-05-30
KR101733414B1 (ko) 2017-05-10
MX2013008012A (es) 2013-08-21
AU2012212992B2 (en) 2015-11-26
EP2670486B1 (en) 2016-04-06
EA025421B1 (ru) 2016-12-30
CY1117564T1 (el) 2017-04-26
US20190100492A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
SMT201600129B (it) Trattamento della lipodistrofia
LT2885010T (lt) Tautopatijos gydymo būdai
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
LT2846809T (lt) Mielosupresijos gydymas
EP2670434A4 (en) TREATMENT OF TAUOPATHIES
DK2717941T3 (da) Behandling af cancer
DK2785349T4 (da) Kombinationsbehandling af cancer
IL231092A0 (en) Treatment of rhinitis
IL233111A0 (en) Preparations for the treatment of inflammation
EP2750709A4 (en) TREATMENT OF KACHEXIE
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
EP2714694A4 (en) BAKTERIOCHLORIMIDE
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii
EP2709665A4 (en) TREATMENT OF PSORIASIS
EP2599177A4 (en) CLAMP PAIR
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
FI20116093L (fi) Vettä käsittelevä laitos
DK2694056T3 (da) Terapeutisk behandling
FR2987258B1 (fr) Kit de biberons
UA22462S (uk) Деталь фасонна компресійна-фланець
UA22461S (uk) Деталь фасонна компресійна-цанга
UA22903S (uk) Масажер
UA22961S (uk) Масажер